1
|
Intercellular crosstalk of hepatic stellate cells in liver fibrosis: New insights into therapy. Pharmacol Res 2020; 155:104720. [PMID: 32092405 DOI: 10.1016/j.phrs.2020.104720] [Citation(s) in RCA: 108] [Impact Index Per Article: 21.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/29/2019] [Revised: 01/08/2020] [Accepted: 02/20/2020] [Indexed: 02/08/2023]
Abstract
Liver fibrosis is a dynamic wound-healing process characterized by the net accumulation of extracellular matrix. There is no efficient antifibrotic therapy other than liver transplantation to date. Activated hepatic stellate cells (HSCs) are the major cellular source of matrix-producing myofibroblasts, playing a central role in the initiation and progression of liver fibrosis. Paracrine signals from resident and inflammatory cells such as hepatocytes, liver sinusoidal endothelial cells, hepatic macrophages, natural killer/natural killer T cells, biliary epithelial cells, hepatic progenitor cells, and platelets can directly or indirectly regulate HSC differentiation and activation. Intercellular crosstalk between HSCs and those "responded" cells has been a critical event involved in HSC activation and fibrogenesis. This review summarizes recent advancement regarding intercellular communication between HSCs and other "responded cells" during liver fibrosis and experimental models of intercellular crosstalk systems, and provides novel ideas for potential antifibrotic therapeutic strategy.
Collapse
|
2
|
Yang Y, Li F, Wei S, Liu X, Wang Y, Liu H, Wang J, Li H, Cai H, Zhao Y. Metabolomics profiling in a mouse model reveals protective effect of Sancao granule on Con A-Induced liver injury. JOURNAL OF ETHNOPHARMACOLOGY 2019; 238:111838. [PMID: 30930257 DOI: 10.1016/j.jep.2019.111838] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/23/2018] [Revised: 03/24/2019] [Accepted: 03/25/2019] [Indexed: 05/15/2023]
Abstract
ETHNOPHARMACOLOGICAL RELEVANCE Sancao granule (SCG) is a traditional Chinese herb formula, which has been used for autoimmune liver disease for decades. Previous study demonstrated that there was an exactly therapeutic effect of SCG on autoimmune hepatitis (AIH) by improving liver function and alleviating the clinical symptoms. However, studies of the mechanism by which SCG alleviates Con A-induced liver injury (CILI) should be complemented. MATERIALS AND METHODS An ultraperformance liquid chromatography with quadrupole time-of-flight mass spectrometry (UHPLC-QTOF/MS)-based metabolomics approach combined with principle component analysis (PCA) and orthogonal projection to latent structures discriminate analysis (OPLS-DA) were integrated applied to obtain metabolites for clarifying mechanisms of disease. RESULTS In accordance with previously study, the present study demonstrated that SCG could obviously improve the liver injury in mouse induced by Con A via downregulating serum biochemical indexes, alleviating the histological damage and inhibiting the neutrophil infiltration in liver tissues. Different expression of 9 metabolites related to 8 pathways, including fatty acid biosynthesis, arachidonic acid metabolisms, linoleic acid metabolisms, sphingolipid metabolisms, fatty acid elongation in mitochondria, glycerophospholipid metabolism, fatty acid metabolism, pyrimidine metabolism were demonstrated responsible for the efficacy of SCG in treating CILI. CONCLUSION In sum up, SCG has been indicated favorable therapeutic effect on Con A induced liver injury. And metabolomics could be a promising approach, which provide insights into mechanisms of SCG in treating CILI.
Collapse
Affiliation(s)
- Yuxue Yang
- Department of Pharmacy, 302 Military Hospital of China, Beijing, China; College of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, China
| | - Fengyi Li
- Center for Diagnosis, Treatment and Research of Infectious Diseases, 302 Military Hospital of China, Beijing, China
| | - Shizhang Wei
- Department of Pharmacy, 302 Military Hospital of China, Beijing, China
| | - Xiaoyi Liu
- Department of Integrative Medical Center, 302 Military Hospital of China, Beijing, China
| | - Yingying Wang
- Department of Pharmacy, 302 Military Hospital of China, Beijing, China; College of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, China
| | - Honghong Liu
- Department of Integrative Medical Center, 302 Military Hospital of China, Beijing, China
| | - Jiabo Wang
- Department of Integrative Medical Center, 302 Military Hospital of China, Beijing, China
| | - Haotian Li
- Department of Pharmacy, 302 Military Hospital of China, Beijing, China
| | - Huadan Cai
- Department of Pharmacy, 302 Military Hospital of China, Beijing, China
| | - Yanling Zhao
- Department of Pharmacy, 302 Military Hospital of China, Beijing, China.
| |
Collapse
|
3
|
Yang Y, Zhang P, Wang Y, Wei S, Zhang L, Wang J, Lu X, Zhou H, Li R, Wen J, Zhou X, Li H, Li K, Zhao Y. Hepatoprotective Effect of San-Cao Granule on Con A-Induced Liver Injury in Mice and Mechanisms of Action Exploration. Front Pharmacol 2018; 9:624. [PMID: 29946260 PMCID: PMC6005824 DOI: 10.3389/fphar.2018.00624] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/07/2017] [Accepted: 05/24/2018] [Indexed: 12/18/2022] Open
Abstract
Objective: San-Cao granule (SCG), a traditional Chinese herb formula, has been used for treating autoimmune hepatitis (AIH) in our clinics for a long time. However, its active ingredients and mechanisms of action were still unknown due to its complicated chemical compositions. In the present study, the pharmacological study of SCG on acute liver injury induced by Concanavalin A (Con A) was performed to provide a scientific evidence for SCG against liver injury. Methods: In order to screen active components and predicate mechanisms of action, an "ingredients-target-disease" interaction network was constructed by network pharmacology. Then, the pharmacological study was performed to evaluate the therapeutic effect and the underlying mechanisms of SCG on Con A-induced liver injury in mice. Results: This research demonstrated the pharmacological effect of SCG on Con A-induced liver injury, which was through improving the liver function, relieving the pathological changes of liver tissue, decreasing the level of pro-inflammatory cytokines, and thus balancing the pro- and anti-inflammatory cytokines. And the anti-inflammatory of SCG may advantage over the ursodeoxycholic acid (UDCA). Network pharmacology analysis revealed that the pharmacological effect of SCG might be related to its active ingredients of taraxanthin, dihydrotanshinone I, isotanshinone I, γ-sitosterol, 3β-acetyl-20,25-epoxydammarane-24α, and δ-7-stigmastenol. The hepatoprotective effect of SCG was reflected by suppressing Con A-induced apoptosis which was mediated by TRAIL and FASL. Conclusion: The combination of network pharmacology and experimental data has revealed the anti-apoptotic effect of SCG against Con A-induced liver injury.
Collapse
Affiliation(s)
- YuXue Yang
- College of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, China
- Department of Pharmacy, 302 Military Hospital of China, Beijing, China
| | - Ping Zhang
- Department of Integrative Medical Center, 302 Military Hospital of China, Beijing, China
| | - Yingying Wang
- College of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, China
- Department of Pharmacy, 302 Military Hospital of China, Beijing, China
| | - Shizhang Wei
- Department of Pharmacy, 302 Military Hospital of China, Beijing, China
| | - Lu Zhang
- College of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, China
- Department of Pharmacy, 302 Military Hospital of China, Beijing, China
| | - Jiabo Wang
- Department of Integrative Medical Center, 302 Military Hospital of China, Beijing, China
| | - Xiaohua Lu
- College of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, China
- Department of Pharmacy, 302 Military Hospital of China, Beijing, China
| | - Houqin Zhou
- College of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, China
- Department of Pharmacy, 302 Military Hospital of China, Beijing, China
| | - Ruisheng Li
- Experimental Laboratory Center, 302 Military Hospital of China, Beijing, China
| | - Jianxia Wen
- College of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, China
- Department of Pharmacy, 302 Military Hospital of China, Beijing, China
| | - Xuelin Zhou
- Department of Pharmacy, 302 Military Hospital of China, Beijing, China
| | - Haotian Li
- Department of Pharmacy, 302 Military Hospital of China, Beijing, China
| | - Kun Li
- Department of Pharmacy, 302 Military Hospital of China, Beijing, China
| | - Yanling Zhao
- Department of Pharmacy, 302 Military Hospital of China, Beijing, China
| |
Collapse
|
4
|
Wei S, Niu M, Wang J, Wang J, Su H, Luo S, Zhang X, Guo Y, Liu L, Liu F, Zhao Q, Chen H, Xiao X, Zhao P, Zhao Y. A network pharmacology approach to discover active compounds and action mechanisms of San-Cao Granule for treatment of liver fibrosis. Drug Des Devel Ther 2016; 10:733-743. [PMID: 26929602 PMCID: PMC4767056 DOI: 10.2147/dddt.s96964] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023] Open
Abstract
ETHNOPHARMACOLOGICAL RELEVANCE San-Cao Granule (SCG) has been used in patients with liver fibrosis for many years and has shown good effect. However, its mechanism of therapeutic action is not clear because of its complex chemical system. The purpose of our study is to establish a comprehensive and systemic method that can predict the mechanism of action of SCG in antihepatic fibrosis. MATERIALS AND METHODS In this study, a "compound-target-disease" network was constructed by combining the SCG-specific and liver fibrosis-specific target proteins with protein-protein interactions, and network pharmacology was used to screen out the underlying targets and mechanisms of SCG for treatment of liver fibrosis. Then, some key molecules of the enriched pathway were chosen to verify the effects of SCG on liver fibrosis induced by thioacetamide (TAA). RESULTS This systematic approach had successfully revealed that 16 targets related to 11 SCG compounds were closely associated with liver fibrosis therapy. The pathway-enrichment analysis of them showed that the TGF-β1/Smad signaling pathway is relatively important. Animal experiments also proved that SCG could significantly ameliorate liver fibrosis by inhibiting the TGF-β1/Smad pathway. CONCLUSION SCG could alleviate liver fibrosis through the molecular mechanisms predicted by network pharmacology. Furthermore, network pharmacology could provide deep insight into the pharmacological mechanisms of Chinese herbal formulas.
Collapse
Affiliation(s)
- Shizhang Wei
- Department of Pharmacy, 302 Hospital of People’s Liberation Army, Beijing, People’s Republic of China
- Pharmacy College, Chengdu University of Traditional Chinese Medicine, Chengdu, People’s Republic of China
| | - Ming Niu
- China Military Institute of Chinese Medicine, 302 Hospital of People’s Liberation Army, Beijing, People’s Republic of China
| | - Jian Wang
- Pharmacy College, Chengdu University of Traditional Chinese Medicine, Chengdu, People’s Republic of China
| | - Jiabo Wang
- China Military Institute of Chinese Medicine, 302 Hospital of People’s Liberation Army, Beijing, People’s Republic of China
| | - Haibin Su
- Liver Failure Therapy and Research Center, 302 Hospital of People’s Liberation Army, Beijing, People’s Republic of China
| | - Shengqiang Luo
- Department of Integrative Medical Center, 302 Hospital of People’s Liberation Army, Beijing, People’s Republic of China
| | - Xiaomei Zhang
- Pharmacy College, Chengdu University of Traditional Chinese Medicine, Chengdu, People’s Republic of China
- Chong Qing Academy of Chinese Traditional Materia Medica, Key Laboratory of Chongqing TCM Resources, Chongqing, People’s Republic of China
| | - Yanlei Guo
- Chong Qing Academy of Chinese Traditional Materia Medica, Key Laboratory of Chongqing TCM Resources, Chongqing, People’s Republic of China
| | - Liping Liu
- Department of Pharmacy, 302 Hospital of People’s Liberation Army, Beijing, People’s Republic of China
| | - Fengqun Liu
- Department of Pharmacy, 302 Hospital of People’s Liberation Army, Beijing, People’s Republic of China
| | - Qingguo Zhao
- Department of Pharmacy, 302 Hospital of People’s Liberation Army, Beijing, People’s Republic of China
| | - Hongge Chen
- Department of Pharmacy, 302 Hospital of People’s Liberation Army, Beijing, People’s Republic of China
| | - Xiaohe Xiao
- China Military Institute of Chinese Medicine, 302 Hospital of People’s Liberation Army, Beijing, People’s Republic of China
| | - Pan Zhao
- Liver Failure Therapy and Research Center, 302 Hospital of People’s Liberation Army, Beijing, People’s Republic of China
- Clinical Trial Center, 302 Hospital of People’s Liberation Army, Beijing, People’s Republic of China
| | - Yanling Zhao
- Department of Pharmacy, 302 Hospital of People’s Liberation Army, Beijing, People’s Republic of China
- Pharmacy College, Chengdu University of Traditional Chinese Medicine, Chengdu, People’s Republic of China
| |
Collapse
|